ArticleDiabetes, obesity & metabolism2026
Baseline and 4-year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsPrediabetes is a prevalent condition associated with increased cardiovascular and renal risk. However, the long-term impact of haemoglobin A1c (HbA1c) within the range defined as prediabetes on kidney function remains unclear. This study aimed to evaluate the association between prediabetes and renal function (estimated glomerular filtration rate [eGFR] and albuminuria) through cross-sectional and prospective analyses over 4 years in a cohort of individuals with no diagnosis of diabetes or established cardiovascular disease. MATERIALS AND
methodsAnalysis using data from 8153 participants in the ILERVAS cohort, a prospective cross-sectional study. Prediabetes was defined as HbA1c 5.7%-6.4% (ADA criteria). Kidney impairment was defined as eGFR <60 mL/min/1.73 m
resultsAt baseline, prediabetes was associated with higher kidney impairment prevalence (17.8% vs. 13.7%; p < 0.001), lower eGFR and increased ACR. Each 1% increase in HbA1c was linked to a 4.6 mL/min/1.73 m
conclusionsHbA1c-defined prediabetes is independently associated with early renal impairment and accelerated kidney function decline. These findings support incorporating renal risk assessment in prediabetes and suggest HbA1c as a marker for chronic kidney disease prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.